the usage of Olverembatinib combined with Inotuzumab Ozogamicin
IIT2022033
Unknown small_molecule active
Quick answer
the usage of Olverembatinib combined with Inotuzumab Ozogamicin for Ph+ ALL is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Ph+ ALL
- Phase
- Unknown
- Modality
- small_molecule
- Status
- active